How does Ozempic work for weight loss?
Ozempic, also known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. [1] Research has shown that Ozempic can also aid in weight loss, particularly in individuals with obesity. It works by slowing gastric emptying, reducing appetite, and increasing feelings of fullness.
Weight loss results with Ozempic
Clinical trials have demonstrated that Ozempic, when used in combination with diet and exercise, can lead to significant weight loss in obese individuals. In a trial involving over 3,200 participants, those receiving semaglutide experienced an average weight loss of 11.2% over 68 weeks, compared to 2.3% in the placebo group. [2] Another study showed similar results, with subjects taking semaglutide losing an average of 10.3% of their initial body weight over 20 weeks. [3]
Mechanisms behind weight loss with Ozempic
Ozempic's weight loss effects are thought to be multifactorial. By increasing GLP-1 levels, it enhances glucose-dependent insulin secretion and decreases glucagon secretion, leading to improved glycemic control. Additionally, GLP-1 has a satiety-enhancing effect, reducing appetite and promoting feelings of fullness. [4]
Comparison to other weight loss treatments
Ozempic has been compared to other weight loss medications, such as liraglutide (Saxenda) and bupropion-naltrexone (Contrave). In a head-to-head trial, semaglutide was found to be more effective in promoting weight loss than liraglutide, with 55.6% of semaglutide-treated participants achieving a 10% or greater weight loss compared to 35.8% of those on liraglutide. [5]
Patent information and exclusivity
Ozempic is marketed by Novo Nordisk, which has patent protection for the medication in the United States until 2035. [6] As the patent expires, generic versions of Ozempic will likely become available, potentially increasing accessibility and affordability for patients.
Side effects and patient concerns
Common side effects of Ozempic include nausea, vomiting, diarrhea, and injection-site reactions. [7] Rare but serious side effects include acute kidney injury, pancreatitis, and medullary thyroid carcinoma. As with any medication, patients should be monitored closely and report any symptoms to their healthcare provider.
Regulatory status and availability
Ozempic is approved in the United States for the treatment of type 2 diabetes and has been granted a label expansion for weight management in individuals with obesity. However, its use for weight loss in the absence of diabetes remains an off-label indication.
Source
[1] https://www.drugpatentrwatch.com/semaglutide/
[2] www.nejm.org/doi/full/10.1056/NEJMoa1707258
[3] www.jaeronline.org/article/S0168-8227(19)30129-7/fulltext
[4] https://link.springer.com/article/10.1007/s11608-020-00735-1
[5] www.nejm.org/doi/full/10.1056/NEJMoa1411893
[6] https://www.drugpatentrwatch.com/semaglutide/
[7] https://www.nlm.nih.gov/medlineplus/druginfo/meds/a619026.html